NXTC
HEALTHCARENextcure Inc
$10.72+1.40 (+15.02%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NXTC Today?
No stock-specific AI insight has been generated for NXTC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.60$15.74
$10.72
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-19.65
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume84K
Avg Volume (10D)—
Shares Outstanding3.6M
NXTC News
21 articles- NextCure 1Q Loss/Shr $1.87 >NXTCMoomoo·May 8, 2026
- NextCure Provides Business Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic CancersYahoo Finance·May 4, 2026
- NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026Yahoo Finance·Apr 21, 2026
- NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerYahoo Finance·Apr 7, 2026
- NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026Yahoo Finance·Mar 31, 2026
- NextCure Provides Business Update and Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- NextCure Provides Business UpdateYahoo Finance·Jan 23, 2026
- NextCure to Present at the Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 20, 2025
- NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data ReadoutsYahoo Finance·Nov 17, 2025
- NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq RulesYahoo Finance·Nov 12, 2025
- Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?Yahoo Finance·Nov 11, 2025
- NextCure Provides Business Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 5, 2025
- Companies Like NextCure (NASDAQ:NXTC) Could Be Quite RiskyYahoo Finance·Oct 18, 2025
- NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United StatesYahoo Finance·Oct 16, 2025
- NextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 4, 2025
- NextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 7, 2025
- Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaYahoo Finance·Jul 24, 2025
- NextCure and Simcere partner to develop SIM0505 for solid tumoursPharmaceutical-technology·Jun 17, 2025
- NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6Yahoo Finance·Jun 16, 2025
- NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024Yahoo Finance·May 30, 2025
All 21 articles loaded
Price Data
Open$9.23
Previous Close$9.32
Day High$10.87
Day Low$9.05
52 Week High$15.74
52 Week Low$4.60
52-Week Range
$4.60$15.74
$10.72
Fundamentals
Market Cap$39M
P/E Ratio—
EPS$-19.65
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume84K
Avg Volume (10D)—
Shares Outstanding3.6M
About Nextcure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—